April 15, 2009
Asahi Kasei Pharma Corporation

License agreement for development and sale of Flivas™ in Korea
Asahi Kasei Pharma concluded a license agreement with Dong-A Pharmaceutical Co., Ltd. (DAP) on April 13, 2009, granting DAP exclusive rights in Korea for the development and sale of naftopidil, an agent for the treatment of benign prostatic hyperplasia (BPH) marketed as Flivas™. DAP will now advance clinical development in preparation for a new drug application in Korea.

BPH is a condition in which an enlarged prostate gland causes urinary symptoms such as discomfort, incontinence, incomplete voiding, and nocturia. Naftopidil is an α1-blocker that suppresses the constriction of smooth muscle in the prostate gland and in the urethra, alleviating the discomfort and other symptoms of BPH.

Flivas™ has played an important role in improving the quality of life for many patients in Japan. As the population ages, Flivas™ will be an increasingly vital therapy for a growing number of patients. The partnership with DAP, a company having a wealth of experience in the field of urology, will facilitate the rapid establishment of a major presence for Flivas™ in the vital Korean market.
Corporate profile of Dong-A Pharmaceutical Co., Ltd.
President: Won-Bae Kim
Head office: Seoul, Korea
Paid-in capital: 51.3 billion won (as of Dec. 31, 2008)
Business line: Production and sale of pharmaceuticals
Net sales: 720.3 billion won (year ended Dec. 31, 2008)
Employees: 2,130
Flivas™ product overview
Dosage: 25 mg, 50 mg, 75 mg
Generic name: Naftopidil
Formulation: Tablets
Indication: Benign prostatic hyperplasia
Manufacturer: Asahi Kasei Pharma Corp.


Adobe Readeris required to view these PDF files.

page top